ImmunoGen is preparing to capitalize on US FDA approval in February for Kadcyla (ado trastuzumab emtansine) - the first approved cancer therapy that incorporates the Waltham, Massachusetts-based company's antibody-drug conjugate (ADC) technology.
INTERVIEW: ImmunoGen prepares to capitalize on Kadcyla
ImmunoGen is preparing to capitalize on US FDA approval in February for Kadcyla (ado trastuzumab emtansine) - the first approved cancer therapy that incorporates the Waltham, Massachusetts-based company's antibody-drug conjugate (ADC) technology.
More from Anticancer
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
More from Therapeutic Category
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.